EU approves Abbott's Humira for pediatric Crohn's disease

11/28/2012 | PharmaTimes (U.K.)

Abbott Laboratories received approval from the European Commission to market Humira, or adalimumab, for patients ages 6 to 17 with severe active Crohn's disease who don't respond to traditional therapy. The approval marks the ninth time that Humira was cleared in the EU.

View Full Article in:

PharmaTimes (U.K.)

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Chief Executive Officer
Center for Improving Value in Healthcare
Denver, CO
Quality Program Manager II, State Programs
Tufts Health Plan
Watertown, MA
Associate Director, Promotion Integrity
Bristol-Myers Squibb
Plainsboro, NJ
Vice President, Medicare Advantage
Baton Rouge, LA
Director, Global Integrity and Compliance, Pharmaceuticals
Fort Worth, TX